مباشر
Endpoints NewsTakeda fortifies orexin potential with more Phase 3 dataEndpoints NewsElicio’s KRAS cancer vaccine fails in Phase 2, shares plummetFierceBiotechAmid US investment tour, J&J makes $1B stop in Florida to upgrade contact lens plantEndpoints NewsGan & Lee's Phase 3 obesity successes; J&J touts multiple myeloma dataFierceBiotechAmgen loses in Harbour antibody patent case, ordered to pay $20M+FierceBiotechIntellia touts ‘paradigm-shifting’ phase 3 data for one-time HAE treatmentBioWorldBiggest gainers and losers for June 8-12, 2026FierceBiotechNeumora to lay off 35% of staff after navacaprant goes 0 for 3 in late-stage depression studiesEndpoints NewsNeumora drug fails two more Phase 3 trials, biotech to lay off 35% of staffClinical OMICsRewriting Cancer Care Through EpigeneticsFierceBiotechTraws defers midphase flu study after negative regulatory reviewEndpoints NewsSix leaders working on LGBTQ+ inclusion in biopharma
BioWorld ٢٦ يناير ٢٠٢٦

Helmholtz Zentrum Fur Infektionsforschung identifies new argyrin derivatives

Helmholtz Zentrum Fur Infektionsforschung identifies new argyrin derivatives

المصدر
المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.